Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: A phase II trial of the North Central Cancer Treatment Group

Cancer

Volumn 97, Issue 10, 2003, Pages 2498-2503

  Jett, James R ^a   Hatfield, Alan K ^b   Hillman, Shauna ^a   Bauman, Michael D ^c   Mailliard, James A ^d   Kugler, John W ^e   Morton, Roscoe F ^f   Marks, Randolph S ^a   Levitt, Ralph ^g  

^a MAYO CLINIC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Siouxland Comm Cancer Consortium   (United States)

^d MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^e IL Oncol Res Assoc Comm C O P   (United States)

^f IA Oncol Res Association Community   (United States)

^g MeritCare Hospital   (United States)

Author keywords

Alternating chemotherapy; Extensive stage; Small cell lung carcioma; Survival

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; CANCER STAGING; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SMALL CELL CARCINOMA; SURVIVAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; ILLINOIS; INDIANA; IOWA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINNESOTA; NEBRASKA; NEOPLASM STAGING; NORTH DAKOTA; PACLITAXEL; SOUTH DAKOTA; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0037694820     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11377     Document Type: Article

References (24)

1. Maksymiuk AW, Jett JR, Earle JD, et al. Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994;12:70-76.
2. Shaw EG, Su JQ, Eagan RT, et al. Prophylactic cranial irradiations in complete responders with small cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol. 1994;12:2327-2332.
3. Chute JP, Venzon DJ, Hankins L, et al. Outcome of patients with small cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc. 1997;72:901-912.
4. Schiller JH, Kim KM, Hutson P, et al. Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1996;14:2345-2352.
5. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Oncology study. J Clin Oncol. 1995;13:1430-1435.
6. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small cell lung cancer. Am J Clin Oncol. 1999;22:517-522.
7. Jacobs SA, Jett JR, Belani, et al. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer [abstract 1814]. Proc Am Soc Clin Oncol. 1999;18: 470a.
8. Andizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in second line treatment of small cell lung cancer: a Phase II study in patients with refractory and sensitive disease. J Clin Oncol. 1997; 15:2090-2096.
9. von Pawel J, Schiller JH, Sheperd FA, et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol. 1999;17:658-667.
10. Smit EF, Fokkema E, Biesma B, et al. A Phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer. 1998;77:347-351.
11. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst. 1991;83:855-861.
12. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alteration of these two regimens in extensive small cell lung cancer. A Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10:282-229.
13. Jett JR, Su JQ, Krook JE, et al. Measurable or assessable disease in lung cancer trials: does it matter? J Clin Oncol. 1994;12:2677-2681.
14. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics. 1987;43: 81-93.
15. Simon R. Optional two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1-10.
16. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony stimulating factor versus standard chemotherapy in extensive stage small cell lung cancer. The Japanese Clinical Oncology Group. J Clin Oncol. 1998;16: 2126-2132.
18. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive stage small cell lung cancer: an intergroup study of the National Cancer Institute of Canada and the Southwest Oncology Group. J Clin Oncol. 1999;17:2300-2308.
19. Medical Research Council. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer. 1989;59:584-590.
20. Giaccone G, Dalesio O, McVie G, et al. Maintenance chemotherapy in small cell lung cancer: long-term results of a randomized trial. J Clin Oncol. 1993;11:1230-1240.
21. Schiller JH, Adak S, Cella DF, et al. Topotecan versus observation after cisplatin plus etoposide in extensive stage small cell lung cancer (E7593): a Phase III trial of ECOG. J Clin Oncol. 2001;19:2114-2122.
22. Noda K, Nisiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compound with etoposide plus cisplatin for extensive stage small cell lung cancer. N Engl J Med. 2002;346:85-91.
23. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol. 2001;19:1734-1749.
24. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 2001;19:3967-3975.